BioSpace News Archive

LifeStance Health Group, Inc. (NASDAQ: LFST), one of the nation’s largest providers of outpatient mental health care, will issue its fourth quarter and full year 2023 earnings release before the market opens on Wednesday, February 28, 2024.

Silk Road Medical, Inc. (Nasdaq: SILK), a company focused on reducing the risk of stroke and its devastating impact, today announced it will report financial results for the fourth quarter and full year 2023 after market close on Wednesday, February 28th, 2024.

Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces it has entered into an agreement to acquire QSAM Biosciences, Inc. (U.S. OTC: QSAM) and its lead investigational drug Samarium-153-DOTMP (153Sm-DOTMP). QSAM is a United States (U.S.) based company developing therapeutic radiopharmaceuticals for primary and metastatic bone cancer.

Arcus Biosciences (NYSE:RCUS) announced that its management team will host a conference call and webcast on Wednesday, February 21, 2024 at 2:00 PM PT / 5:00 PM ET to discuss pipeline updates and details of the Company’s financial results for the quarter and year ended December 31st, 2023.

Protagonist Therapeutics, Inc. (NASDAQ:PTGX) (“Protagonist” or the “Company”) today announced publication in the New England Journal of Medicine (NEJM) of the Phase 2b FRONTIER 1 trial evaluating JNJ-2113 in adults living with moderate-to-severe plaque psoriasis (PsO).

Bicycle Therapeutics plc technology, today announced that management will participate in a fireside chat at the Oppenheimer 34th Annual Healthcare Life Sciences Conference on February 14, 2024, at 10 a.m. ET.

Today, Two Labs, an Envision Pharma Company and industry leader in pharma services, officially launched its Sunshine Transparency and Aggregate Spend service.

Repligen Corporation (NASDAQ:RGEN) today announced that the Company will report its fourth quarter 2023 financial results on Wednesday, February 21, 2024.

PepGen Inc. today announced the pricing of an underwritten offering of 7,530,000 shares of its common stock at a price to the public of $10.635 per share.

Anavex Life Sciences Corp. today reported financial results for its fiscal quarter ended December 31, 2023.